openPR Logo
Press release

OTC Cough, Cold & Allergy Medicine Market: Future Forecast Indicates Impressive Growth Rate by 2022 | Key Player are Sanofi-Aventis, Johnson & Johnson Service Inc., Reckitt Benckiser Group Plc., Novartis AG, GlaxoSmithKline Plc., etc.

11-28-2018 02:03 PM CET | Health & Medicine

Press release from: Fact.MR

OTC Cough, Cold & Allergy Medicine Market: Future Forecast

An up-to-date research report has been disclosed by Fact.MR highlighting the titled “OTC Cough, Cold & Allergy Medicine Market: Future Forecast Indicates Impressive Growth Rate by 2022” which delivers an outlook of current market value as well as the expected forecast including Rate on Investment (ROI) together with growing CAGR of 4.9% during 2017-2022. The report studies the OTC Cough Cold & Allergy Medicine Market Worldwide, especially in North America, Europe, Southeast Asia, India and Other Regions with production, size, growth, revenue, consumption, import and export in these regions.

Request 100 Page Sample Report from Here - https://www.factmr.com/connectus/sample?flag=S&rep_id=71

Very few individuals consult doctors for common conditions such as cold, cough and allergies; most of them opt for OTC medicines instead.  In the view of such prominent practices, the global sales of the OTC cough, cold and allergy medicines have remained propped up for the past decade or so. Cough, cold and allergy medicines are one of most common OTC (over-the-counter) categories, however, physicians recommend their use only for minor health issues. In many countries, there are certain laws enforced on directs sales of these medicines in order to ensure consumer safety.  In addition, these medicines offer extreme convenience to a modern consumer, living a fast-paced life. The aforementioned factors are expected to reflect favorably on the global OTC cough, cold and allergy medicines market over the next five years. Moreover, an increasing number of immunosuppressed individuals and rising global geriatric population is also expected to further drive the demand OTC medicines for cough, cold and allergy.  The recent study conducted by Fact.MR reveals that the global OTC cough, cold and allergy medicine market is poised to increase at a CAGR of 4.9% during 2017 to 2022 to reach a valuation of around US$ 37,300 Mn.

Asia-Pacific excluding Japan (APEJ) to Remain the Largest Market for OTC Cough, Cold and Allergy Medicines

Asia-Pacific excluding Japan (APEJ) is projected to remain the most lucrative market for OTC cough, cold and allergy medicines throughout the forecast period. In terms of revenue, APEJ is anticipated to account for an impressive share of the global market in 2017 and beyond. The region’s proximity to air pollution has led to the rise in prevalence of various respiratory disorders. Moreover, acceptance rate of OTC medicines is extremely high in the region owing to their low cost and convenience of purchase.

By drug type, antihistamine is projected to account for more than one-third share of the market in terms of revenue by 2017-end. Antihistamines drugs reduce the release of histamine from histamine-1 receptors and are commonly used for treating allergic reactions such as inflammation (redness), swelling (edema), watery eyes or runny nose and sneezing.

To View Full Global Market Research Report Click Here - https://www.factmr.com/report/71/otc-cough-cold-allergy-medicine-market

Pharmacies will remain the leading OTC channel for sales of cough, cold and allergy medicines during the assessment period.  Meanwhile, drug store OTC channel segment is expected to account for the second largest revenue share of the market by 2017-end.

By dosage, the tablet segment is estimated to account for more than 33% revenue share of the market and is expected to reach a valuation of around US$ 12,400 Mn towards the end of the forecast period.

Competition Tracking

Key companies profiled in Fact.MR’s report include Sanofi-Aventis, Johnson & Johnson Service, Inc., Reckitt Benckiser Group Plc., Novartis AG, GlaxoSmithKline Plc., AstraZaneca Plc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Prestige Brands Holdings, Inc., Procter & Gamble Co., Bristol-Myers Squib Co., Merck & Co., and Allergen. Many of these market players are actively focusing on increasing their market presence and development of more efficient products.

Table of Content:

Global OTC Cough, Cold and Allergy Medicines Market - Executive Summary
Global OTC Cough, Cold and Allergy Medicines Market Overview
2.1. Introduction

       2.1.1. Global OTC Cough, Cold and Allergy Medicines Market Taxonomy

       2.1.2. Global OTC Cough, Cold and Allergy Medicines Market Definition

2.2. Global OTC Cough, Cold and Allergy Medicines Market Size (US$ Mn) and Forecast, 2012-2022

       2.2.1. Global OTC Cough, Cold and Allergy Medicines Market Y-o-Y Growth

2.3. Global OTC Cough, Cold and Allergy Medicines Market Dynamics

       2.3.1. Drivers

       2.3.2. Restraints

       2.3.3. Trends

Continued…………………………..

Buy Useful Figures about Global Market Report from Here - https://www.factmr.com/checkout/71/S

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

Fact.MR
11140 Rockville Pike
Suite 400, Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release OTC Cough, Cold & Allergy Medicine Market: Future Forecast Indicates Impressive Growth Rate by 2022 | Key Player are Sanofi-Aventis, Johnson & Johnson Service Inc., Reckitt Benckiser Group Plc., Novartis AG, GlaxoSmithKline Plc., etc. here

News-ID: 1405365 • Views:

More Releases from Fact.MR

USA Demand for Microbiome Skincare Products in USA Outlook 2025-2035: Key Developments and Future Scope
USA Demand for Microbiome Skincare Products in USA Outlook 2025-2035: Key Develo …
The U.S. microbiome skincare market is projected to experience rapid, data-driven growth over the next decade, driven by rising consumer awareness, ingredient innovation, and the integration of personalized diagnostics. Analysts estimate the U.S. microbiome skincare segment at approximately USD 0.13 billion in 2025, with a projected increase to USD 0.35 billion by 2035, representing a compound annual growth rate (CAGR) of 10.4%. To access the complete data tables and in-depth insights,
USA Demand for Lubricants in USA Outlook 2025-2035: Key Developments and Future Scope
USA Demand for Lubricants in USA Outlook 2025-2035: Key Developments and Future …
The U.S. lubricants market is projected to experience steady growth through 2035, driven by shifts in mobility, industrial demand, and sustainability trends. The market was valued at approximately $41.2 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 2.5%, reaching $52 billion by 2035. To access the complete data tables and in-depth insights, request a Discount On The Report here: https://www.factmr.com/connectus/sample?flag=S&rep_id=12463
European Demand for Intermodal Freight Transportation in UK Outlook 2025-2035: Key Developments and Future Scope
European Demand for Intermodal Freight Transportation in UK Outlook 2025-2035: K …
"Demand for intermodal freight transport connecting the UK and continental Europe is projected to grow at a CAGR of 6.8% between 2025 and 2035, driven by rising trade volumes, decarbonization mandates, and digital logistics innovations. The intermodal market, encompassing rail, short-sea shipping, and last-mile road delivery, is expected to handle over 18 million TEUs (twenty-foot equivalent units) annually by 2035, up from 10.2 million TEUs in 2025. To access the complete
USA Demand for Hydroxyapatite in USA Outlook 2025-2035: Key Developments and Future Scope
USA Demand for Hydroxyapatite in USA Outlook 2025-2035: Key Developments and Fut …
The United States hydroxyapatite (HAp) market is projected to experience sustained, data-driven growth from 2025 through 2035, fueled by rising clinical demand, technological innovation, and expanded applications in regenerative medicine. Market modeling indicates that U.S. consumption of hydroxyapatite will nearly double over the next decade, with strong adoption in orthopedic, dental, and advanced biomaterial sectors. To access the complete data tables and in-depth insights, request a Discount On The Report here:

All 5 Releases


More Releases for OTC

Lawsuit filed for Investors who lost money with shares of adidas AG (OTC: ADDYY, …
An investor, who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF), filed a lawsuit over alleged violations of Federal Securities Laws by adidas AG in connection with certain allegedly false and misleading statements. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF) have certain options and for certain investors are short and strict deadlines running. Deadline: June 27, 2023. adidas AG (OTC: ADDYY, OTC: ADDDF) investors should contact
Investigation for Investors in adidas AG (OTC: ADDYY, OTC: ADDDF) announced over …
An investigation on behalf of investors in shares of adidas AG (OTC: ADDYY, OTC: ADDDF) was announced over potential breaches of fiduciary duties by certain officers and directors at adidas AG. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain adidas AG officers and
AMERICAN HEMP VENTURES INC (OTC: AMHV) TO BECOME YOUNEEQAI TECHNICAL SERVICES In …
FOR IMMEDIATE RELEASE Denver Colorado, March 31, 2023, American Hemp Ventures, Inc. (OTC: AMHV) announced today that its name has changed effective immediately to YouneeqAI Technical Services inc. (OTC: YQAI) reflecting the Company's new focus into cookie-less AI technology services. The current management team has over 50 years of experience in technology services and innovation. Murray Galbraith, YQAI's CEO, is the Founder of YouneeqAI's software solution and has operated several private technology
Investigation announced for Investors who lost money with shares of adidas AG (O …
An investigation was announced for investors of adidas AG (OTC: ADDYY, OTC: ADDDF) shares over potential securities laws violations by adidas AG. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of adidas AG (OTC: ADDYY,
Fuel Cell Market Technological Trends and Business Opportunities 2021 To 2026; P …
MarketInsightsReports has published a report titled global Fuel Cell Market research report 2021 that is a detailed observation of several aspects, including the rate of growth, technological advances, and different methodologies implemented by the primary current market players. The report is based on a collective analysis of data, which is obtained through primary and secondary research. It provides a systematic approach to the current and prospective scenario of this market. The
Deadline on Nov. 9th upcoming in Lawsuit for Investors in Harborside Inc. (OTC: …
The Shareholders Foundation announced that a deadline is coming up on November 9, 2020 in the lawsuit filed for certain investors of Harborside Inc. (OTC: HSDEF, OTC: HBORF). Investors who purchased shares of Harborside Inc. (OTC: HSDEF, OTC: HBORF) have certain options and there are strict and short deadlines running. Deadline: November 9, 2020. Harborside Inc. stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to